Cue Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cue Biopharma, Inc. on October 8, 2024. The report details the results of a Special Meeting of Stockholders held on the same date and the subsequent filing of a Certificate of Amendment with the State of Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions regarding capital structure and does not contain financial performance data.
Material Changes
On October 8, 2024, the Company's stockholders approved an amendment to its Amended and Restated Certificate of Incorporation. The material changes include:
- Increase in authorized capital stock from 110,000,000 to 210,000,000 shares.
- Increase in authorized common stock from 100,000,000 to 200,000,000 shares.
Voting Results and Management Commentary
Stockholders voted on two proposals at the Special Meeting. Proposal 1, regarding the increase in authorized shares, was approved. The voting results were as follows:
- For: 29,291,818 votes
- Against: 7,409,258 votes
- Abstain: 499,006 votes
Proposal 2, concerning the adjournment of the meeting to solicit further proxies if necessary, was also approved but was deemed unnecessary as a quorum was present and sufficient votes were received for Proposal 1.
Investor Verification Checklist
- Verify the exact number of authorized shares post-amendment (210,000,000 total; 200,000,000 common).
- Review the full text of the Certificate of Amendment filed as Exhibit 3.1 for any additional terms.
- Confirm the impact of the increased share authorization on potential future dilution.
- Check the Company's Proxy Statement filed on September 10, 2024, for the rationale behind the amendment.